Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Neuropsychological Profile and Cognitive Trajectories of Patients With Biomarker Evidence of Alzheimer Disease or Dementia With Lewy bodies.

Neurology·2026
Same author

Practice effects as a dynamic biomarker of early cognitive change in far-from-onset Huntington's disease.

Brain communications·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Atrophy signature for alpha-synuclein copathology in Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Synucleinopathy-like clinical features and biologically defined synuclein seeding in PSP-Parkinsonism: an imperfect match.

NPJ Parkinson's disease·2026
Same author

Prognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Agnès Pérez-Millan1,2, Beatriz Bosch-Capdevila1, Sergi Borrego-Écija1

  • 1Alzheimer's disease and other cognitive disorders Group. Service of Neurology, Hospital Clínic de Barcelona. Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

自体主导性阿尔茨海默病 (ADAD) 突变携带者显示大脑不对称性 (CAI) 的增加,这与疾病生物标志物相关. 这种大脑不对称性标志物 (CAI) 在有症状的个体中随着时间的推移显著增加,这表明其具有早期检测和监测的潜力.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 神经学 神经学
  • 医疗成像医学成像

背景情况:

  • 皮层不对称指数 (CAI) 量化了大脑的不对称性,在零星的阿尔茨海默病 (AD) 中观察到的水平更高.
  • 这项研究调查了自体主导阿尔茨海默病 (ADAD) 的无症状 (AMC) 和症状 (SMC) 突变载体的CAI.

研究的目的:

  • 评估皮质不对称指数 (CAI) 作为自体主导阿尔茨海默病 (ADAD) 的潜在生物标志物.
  • 评估无症状 (AMC) 和症状 (SMC) ADAD突变载体的CAI及其与疾病进展和生物标志物的相关性.

主要方法:

  • 使用T1加权的MRI数据来自两个队列:巴塞罗那诊所 (N=56) 和DIAN-OBS (N=464).
  • 使用Freesurfer和开源管道计算CAI;分析了横截面和纵向数据,包括脑脊液 (CSF) 和血神经纤维光链 (NfL) 水平.
  • 评估了CAI,年龄,预计发病年 (EYO),迷你精神状态检查 (MMSE) 得分和NfL水平之间的相关性;检查了APOE基因型效应.

主要成果:

  • CAI将ADAD突变载体 (AMC和SMC) 与健康对照 (CTR) 区分开来,并从CTR和AMC中确定了SMC-AD.
  • 携带者和SMC的CAI升高与较高的血NfL,高级EYO和较低的MMSE得分相关.
  • 从长度上看,在DIAN队列中的SMC和SMC-AD个体中,CAI随着时间的推移显著增加.

结论:

  • ADAD个体表现出增加的大脑不对称性,随着疾病的进展,与关键的AD生物标志物相关.
  • 在症状ADAD的个体中,CAI显示显著的纵向增加,突出了其对疾病监测的潜力.
  • CAI是早期检测和跟踪AD在自体主导阿尔茨海默氏症进展的有希望的工具.